This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sasai, K. Articles by Curran, T. Search for Related Content PubMed PubMed Citation Articles by Sasai, K. Articles by Curran, T.

Shh Pathway Activity Is Down-Regulated in Cultured Medulloblastoma Cells: Implications for Preclinical Studies

Departments of ¹ Developmental Neurobiology, ² Genetics and Tumor Cell Biology, ³ Hartwell Center, and ⁴ Pathology, Saint Jude Children's Research Hospital, Memphis, Tennessee

Requests for reprints: Tom Curran, Department of Developmental Neurobiology, Saint Jude Children's Research Hospital, 332 North Lauderdale Street, Memphis, TN 38105. Phone: 901-495-2255; Fax: 901-495-2270; E-mail: tom.curran{at}stjude.org.

Gene expression profiling indicates that the Sonic Hedgehog (Shh) pathway is active in 30% of human medulloblastomas, suggesting that it could provide a useful therapeutic target. Previously, we showed that spontaneous medulloblastomas in Ptc1^+/–p53^–/– mice could be eradicated by treatment with a small-molecule inhibitor (HhAntag) of Smoothened (Smo). Here, we compared the responses of mouse medulloblastoma cells propagated in flank allografts, either directly or after culture in vitro, to HhAntag. We found that Shh pathway activity was suppressed in medulloblastoma cells cultured in vitro and it was not restored when these cells were transplanted into the flank of nude mice. The growth of these transplanted tumor cells was not inhibited by treatment of mice with doses of HhAntag that completely suppressed Smo activity. Interestingly, tumor cells transplanted directly into the flank maintained Smo activity and were sensitive to treatment with HhAntag. These findings indicate that propagation of tumor cells in culture inhibits Smo activity in a way that cannot be reversed by transplantation in vivo, and they raise concerns about the use of cultured tumor cells to test the efficacy of Shh pathway inhibitors as anticancer therapies. (Cancer Res 2006; 66(8): 4215-22)

This article has been cited by other articles:

				R. J. Ward, L. Lee, K. Graham, T. Satkunendran, K. Yoshikawa, E. Ling, L. Harper, R. Austin, E. Nieuwenhuis, I. D. Clarke, et al. Multipotent CD15+ Cancer Stem Cells in Patched-1-Deficient Mouse Medulloblastoma Cancer Res., June 1, 2009; 69(11): 4682 - 4690. [Abstract] [Full Text] [PDF]

				V. C. Daniel, L. Marchionni, J. S. Hierman, J. T. Rhodes, W. L. Devereux, C. M. Rudin, R. Yung, G. Parmigiani, M. Dorsch, C. D. Peacock, et al. A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In vitro Cancer Res., April 15, 2009; 69(8): 3364 - 3373. [Abstract] [Full Text] [PDF]

				J. D. Kessler, H. Hasegawa, S. N. Brun, B. A. Emmenegger, Z.-J. Yang, J. W. Dutton, F. Wang, and R. J. Wechsler-Reya N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma Genes & Dev., January 15, 2009; 23(2): 157 - 170. [Abstract] [Full Text] [PDF]

				L. Miele, N. Takebe, and S. P. Ivy The Cancer Stem Cell Hypothesis, Embryonic Signaling Pathways, and Therapeutics: Targeting an Elusive Concept ASCO Educational Book, January 1, 2009; 2009(1): 145 - 156. [Abstract] [Full Text] [PDF]

				Q. Shu, K. K. Wong, J. M. Su, A. M. Adesina, L. T. Yu, Y. T. M. Tsang, B. C. Antalffy, P. Baxter, L. Perlaky, J. Yang, et al. Direct Orthotopic Transplantation of Fresh Surgical Specimen Preserves CD133+ Tumor Cells in Clinically Relevant Mouse Models of Medulloblastoma and Glioma Stem Cells, June 1, 2008; 26(6): 1414 - 1424. [Abstract] [Full Text] [PDF]

				M. Evangelista, H. Tian, and F. J de Sauvage The Hedgehog Signaling Pathway in Cancer Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 479 - 486. [Abstract] [Full Text] [PDF]

				O. J. Becher, D. Hambardzumyan, E. I. Fomchenko, H. Momota, L. Mainwaring, A.-M. Bleau, A. M. Katz, M. Edgar, A. M. Kenney, C. Cordon-Cardo, et al. Gli Activity Correlates with Tumor Grade in Platelet-Derived Growth Factor-Induced Gliomas Cancer Res., April 1, 2008; 68(7): 2241 - 2249. [Abstract] [Full Text] [PDF]

				R. K. Lindemann Stroma-Initiated Hedgehog Signaling Takes Center Stage in B-Cell Lymphoma Cancer Res., February 15, 2008; 68(4): 961 - 964. [Abstract] [Full Text] [PDF]

				A. Rossi, V. Caracciolo, G. Russo, K. Reiss, and A. Giordano Medulloblastoma: From Molecular Pathology to Therapy Clin. Cancer Res., February 15, 2008; 14(4): 971 - 976. [Abstract] [Full Text] [PDF]

				X. Q. Lun, H. Zhou, T. Alain, B. Sun, L. Wang, J. W. Barrett, M. M. Stanford, G. McFadden, J. Bell, D. L. Senger, et al. Targeting Human Medulloblastoma: Oncolytic Virotherapy with Myxoma Virus Is Enhanced by Rapamycin Cancer Res., September 15, 2007; 67(18): 8818 - 8827. [Abstract] [Full Text] [PDF]

				M. Lauth, A. Bergstrom, T. Shimokawa, and R. Toftgard Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists PNAS, May 15, 2007; 104(20): 8455 - 8460. [Abstract] [Full Text] [PDF]

				K. Sasai, J. T. Romer, H. Kimura, D. E. Eberhart, D. S. Rice, and T. Curran Medulloblastomas Derived from Cxcr6 Mutant Mice Respond to Treatment with a Smoothened Inhibitor Cancer Res., April 15, 2007; 67(8): 3871 - 3877. [Abstract] [Full Text] [PDF]

				M. Evangelista, H. Tian, and F. J. de Sauvage The hedgehog signaling pathway in cancer. Clin. Cancer Res., October 15, 2006; 12(20): 5924 - 5928. [Abstract] [Full Text] [PDF]